The hurdle of antiandrogen drug resistance: drug design strategies.
about
A potential regulatory loop between Lin28B:miR‑212 in androgen-independent prostate cancer.Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistanceA phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.
P2860
The hurdle of antiandrogen drug resistance: drug design strategies.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
The hurdle of antiandrogen drug resistance: drug design strategies.
@en
type
label
The hurdle of antiandrogen drug resistance: drug design strategies.
@en
prefLabel
The hurdle of antiandrogen drug resistance: drug design strategies.
@en
P2860
P1476
The hurdle of antiandrogen drug resistance: drug design strategies.
@en
P2093
Jill A Trendel
P2860
P304
P356
10.1517/17460441.2013.855194
P407
P577
2013-11-09T00:00:00Z